These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34820393)

  • 1. Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19.
    Masiá M; Padilla S; García JA; García-Abellán J; Navarro A; Guillén L; Telenti G; Mascarell P; Botella Á; Gutiérrez F
    Front Med (Lausanne); 2021; 8():749657. PubMed ID: 34820393
    [No Abstract]   [Full Text] [Related]  

  • 2. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
    Marconi VC; Ramanan AV; de Bono S; Kartman CE; Krishnan V; Liao R; Piruzeli MLB; Goldman JD; Alatorre-Alexander J; de Cassia Pellegrini R; Estrada V; Som M; Cardoso A; Chakladar S; Crowe B; Reis P; Zhang X; Adams DH; Ely EW;
    Lancet Respir Med; 2021 Dec; 9(12):1407-1418. PubMed ID: 34480861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial.
    Karampitsakos T; Papaioannou O; Tsiri P; Katsaras M; Katsimpris A; Kalogeropoulos AP; Malakounidou E; Zarkadi E; Tsirikos G; Georgiopoulou V; Sotiropoulou V; Koulousousa E; Chourpiliadi C; Matsioulas A; Lagadinou M; Sampsonas F; Akinosoglou K; Marangos M; Tzouvelekis A
    Clin Microbiol Infect; 2023 Mar; 29(3):372-378. PubMed ID: 36273769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.
    Bryushkova EA; Skatova VD; Mutovina ZY; Zagrebneva AI; Fomina DS; Kruglova TS; Akopyan AA; Strazhesko ID; Lukyanov SA; Tkacheva ON; Lysenko MA; Chudakov DM
    PLoS One; 2022; 17(8):e0273340. PubMed ID: 36001576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19.
    Reid NK; Joyner KR; Lewis-Wolfson TD
    Ann Pharmacother; 2023 Jul; 57(7):769-775. PubMed ID: 36314277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort.
    Karolyi M; Gruebl A; Omid S; Saak M; Pawelka E; Hoepler W; Kelani H; Kuran A; Laferl H; Ott C; Pereyra D; Santol J; Seitz T; Traugott M; Assinger A; Wenisch C; Zoufaly A
    Infection; 2023 Aug; 51(4):851-858. PubMed ID: 36083403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis.
    Cherian JJ; Eerike M; Bagepally BS; Das S; Panda S
    Front Pharmacol; 2022; 13():1004308. PubMed ID: 36330085
    [No Abstract]   [Full Text] [Related]  

  • 9. Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation.
    Padilla S; Polotskaya K; Fernández M; Gonzalo-Jiménez N; de la Rica A; García JA; García-Abellán J; Mascarell P; Gutiérrez F; Masiá M
    J Antimicrob Chemother; 2022 Jul; 77(8):2257-2264. PubMed ID: 35534369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.
    Ely EW; Ramanan AV; Kartman CE; de Bono S; Liao R; Piruzeli MLB; Goldman JD; Saraiva JFK; Chakladar S; Marconi VC;
    Lancet Respir Med; 2022 Apr; 10(4):327-336. PubMed ID: 35123660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone.
    Wong CKH; Lau KTK; Au ICH; Xiong X; Chung MSH; Leung BYC; Lau EHY; Cowling BJ
    Front Pharmacol; 2022; 13():866441. PubMed ID: 35707401
    [No Abstract]   [Full Text] [Related]  

  • 12. Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials.
    Selvaraj V; Finn A; Lal A; Khan MS; Dapaah-Afriyie K; Carino GP
    EClinicalMedicine; 2022 Jul; 49():101489. PubMed ID: 35677732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States.
    Ohsfeldt R; Kelton K; Klein T; Belger M; Mc Collam PL; Spiro T; Burge R; Ahuja N
    Clin Ther; 2021 Nov; 43(11):1877-1893.e4. PubMed ID: 34732289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes among Hospitalized COVID-19 Patients Who Received Baricitinib or Tocilizumab in Addition to Standard of Care.
    Walker CP; Hurlock NP; Deb S
    Diseases; 2024 May; 12(5):. PubMed ID: 38785762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Tocilizumab vs Baricitinib in Clinical Outcomes Among Hospitalized Patients With COVID-19: Experience From a Public Hospital System in New York City.
    Sunny S; Tran A; Lee J; Abdallah M; Chaudhry N; Quale J
    Open Forum Infect Dis; 2023 Aug; 10(8):ofad426. PubMed ID: 37608917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Janus kinase inhibitors for the treatment of COVID-19.
    Kramer A; Prinz C; Fichtner F; Fischer AL; Thieme V; Grundeis F; Spagl M; Seeber C; Piechotta V; Metzendorf MI; Golinski M; Moerer O; Stephani C; Mikolajewska A; Kluge S; Stegemann M; Laudi S; Skoetz N
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD015209. PubMed ID: 35695334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis.
    Albuquerque AM; Eckert I; Tramujas L; Butler-Laporte G; McDonald EG; Brophy JM; Lee TC
    Clin Microbiol Infect; 2023 Jan; 29(1):13-21. PubMed ID: 35863630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
    RECOVERY Collaborative Group
    Lancet; 2022 Jul; 400(10349):359-368. PubMed ID: 35908569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study.
    Roddy J; Wells D; Schenck K; Santosh S; Santosh S
    Crit Care Explor; 2022 May; 4(5):e0702. PubMed ID: 35783551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19.
    Peterson JH; Paranjape NS; Grundlingh N; Priestley JL
    Crit Care Med; 2023 Mar; 51(3):337-346. PubMed ID: 36729439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.